Biotechnology

Shares of Canadian cannabis-products maker CannTrust drop, then rebound, after the company reveals a preliminary quarterly loss and announces new share issuance.

Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.

As the healthcare sector sells off, it's time to look for attractive value. You don't have to go any further than Amgen.

Danaher reports first-quarter earnings that beat analysts' estimates though revises forward guidance on costs related to acquisition of GE's biopharma business.

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Few parts of the market have more volatility than the small caps in this sector.

Healthcare giant Johnson & Johnson reports first-quarter earnings lower than a year earlier but still above analysts' forecasts.

Drugmaker Catalent reaches an agreement to buy closely held Paragon Bioservices, the latest deal in the burgeoning gene-therapy treatment space.

A low-risk countertrend options trade may be worth a look in this name.

Here are updates on small biotech/biopharma names I have profiled before.